Primary central nervous system lymphoma: Part 2: Modern therapeutic management and future directions

Rimas Vincas Lukas*, Vinai Gondi, Roger Stupp, Jeffrey J Raizer

*Corresponding author for this work

Research output: Contribution to journalArticle

2 Scopus citations

Abstract

Primary central nervous system (CNS) lymphoma, a rare CNS neoplasm associated with high mortality, is responsive to therapeutic interventions. In Part 1 of our two-part coverage of this entity, we provided an overview of the epidemiology of primary CNS lymphoma, followed by a discussion of the diagnostic and staging evaluation, and a review of current prognostication systems. In Part 2, we discuss the management of primary CNS lymphoma, focusing in particular on systemic therapies and radiation. With respect to systemic therapies, we provide details of a variety of regimens built around a backbone of high-dose methotrexate. Future directions for the treatment of primary CNS lymphoma are reviewed as well. These include optimization of consolidation regimens and the pursuit of novel agents.

Original languageEnglish (US)
Pages (from-to)e11-e19
JournalONCOLOGY (United States)
Volume32
Issue number2
StatePublished - Jan 1 2018

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Primary central nervous system lymphoma: Part 2: Modern therapeutic management and future directions'. Together they form a unique fingerprint.

  • Cite this